Chen Hui, Lu Jialin, Wang Danru, Sui Lihao, Xu Sheng
National Key Laboratory of Medical Immunology, The Second Military Medical University, Shanghai 200082, China.
National Key Laboratory of Medical Immunology, The Second Military Medical University, Shanghai 200082, China. *Corresponding author, E-mail:
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2023 Dec;39(12):1125-1131.
Lectins are proteins responsible for recognizing the signals of sugar molecules in the body. Sialic acid-binding immunoglobulin-like lectins (Siglecs) regulate the innate and adaptive immune responses in the tumor microenvironment by recognizing the glycan structure containing sialic acid and mediating downstream signals through immune receptor tyrosine inhibitory motifs. In recent years, a variety of tumor treatment strategies targeting the sialic acid-Siglecs axis have been introduced, including sialoglycoprotein-mediated drug delivery and antibody mediated inhibition of Siglecs from recognizing tumor surface ligands. In the future, by combining with glycoprotein nanotherapy, antibody therapy and gene therapy, Siglecs can be used to accurately locate tumor targets and release the anti-tumor immunity, so as to achieve the purpose of effective cure of tumors.
凝集素是负责识别体内糖分子信号的蛋白质。唾液酸结合免疫球蛋白样凝集素（Siglecs）通过识别含有唾液酸的聚糖结构并通过免疫受体酪氨酸抑制基序介导下游信号，来调节肿瘤微环境中的固有免疫和适应性免疫反应。近年来，已引入了多种针对唾液酸-Siglecs轴的肿瘤治疗策略，包括唾液酸糖蛋白介导的药物递送以及抗体介导的抑制Siglecs识别肿瘤表面配体。未来，通过与糖蛋白纳米疗法、抗体疗法和基因疗法相结合，Siglecs可用于准确定位肿瘤靶点并释放抗肿瘤免疫力，从而达到有效治愈肿瘤的目的。
